Melanoma BRAF fusions--response
Clin Cancer Res
.
2014 Dec 15;20(24):6632.
doi: 10.1158/1078-0432.CCR-14-1152.
Authors
Katherine E Hutchinson
1
,
Jeffrey S Ross
2
,
Philip J Stephens
3
,
Vincent A Miller
3
,
Jeffrey A Sosman
4
,
William Pao
5
Affiliations
1
Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
2
Foundation Medicine, Inc., Cambridge, Massachusetts. Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York.
3
Foundation Medicine, Inc., Cambridge, Massachusetts.
4
Department of Medicine, Division of Hematology-Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
5
Department of Medicine, Division of Hematology-Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee. william.pao@vanderbilt.edu.
PMID:
25512636
PMCID:
PMC4617643
DOI:
10.1158/1078-0432.CCR-14-1152
No abstract available
Publication types
Letter
Comment
MeSH terms
Female
Humans
Male
Melanoma / drug therapy*
Melanoma / genetics*
Proto-Oncogene Proteins B-raf / genetics*
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics*
Substances
Proto-Oncogene Proteins B-raf
Grants and funding
K24 CA097588/CA/NCI NIH HHS/United States